Samsung Bioepis
UK High Court rules against AbbVie’s Humira patents
March 6, 2017Sales and Marketing AbbVie, Biogen, Fujifilm Kyowa Kirin Biologics, Humira, Samsung Bioepis, biosimilar
The UK High Court has ruled that two of AbbVie patents, related to dosing regimens for rheumatoid arthritis, psoriasis and …
Samsung Bioepis Humira biosimilar gets accepted for EMA review
July 18, 2016Research and Development, Sales and Marketing EMA, Humira, Samsung Bioepis, application
The European Medicines Agency (EMA) has accepted for review the marketing authorisation application from Samsung Bioepis for their biosimilar version …
New data on biosimilars of the big three anti-TNF drugs presented at EULAR 2016
June 8, 2016Research and Development, Sales and Marketing Benepali, Biogen, Enbrel, Flixabi, Humira, Remicade, Samsung Bioepis, biosimilars, eular 2016, sb5
Samsung Bioepis has presented data at EULAR 2016 on three biosimilars of the highly selling anti-TNF drugs Remicade (infliximab), Enbrel …
EU green-lights Samsung Bioepis, Biogen’s Remicade biosimilar Flixabi
May 31, 2016Manufacturing and Production, Research and Development, Sales and Marketing Biogen, Samsung Bioepis, biosimilar, drug trial, regulation, research
Samsung Bioepis and partner Biogen (Nasdaq: BIIB) said the European Commission has approved Flixabi, a biosimilar version of Johnson & …
Samsung Bioepis takes AbbVie to court over attempts to delay Humira biosimilars
April 5, 2016Manufacturing and Production, Research and Development, Sales and Marketing AbbVie, Biogen, Humira, Samsung Bioepis, biosimilars, rheumatoid arthritis
Samsung Bioepis has filed a lawsuit against Abbvie (NYSE: ABBV) to stop the maker of the world’s bestselling drug Humira …
Samsung Bioepis’ Remicade biosimilar set for CHMP verdict
March 31, 2016Medical Communications, Sales and Marketing Flixabi, Remicade, Samsung Bioepis, biosimilars, infliximab
Samsung Bioepis has confirmed that the European Commission’s scientific committee, the CHMP, is this week discussing the approval of its …
First Enbrel biosimilar launches in UK
February 16, 2016Manufacturing and Production, Research and Development Enbrel, Samsung Bioepis, eternacept, rheumatoid arthritis
Following its approval by the European Commission in January, Benepali has become the first biosimilar of Pfizer/Amgen’s Enbrel (etanercept) to …
Samsung beats pharma to develop first EU-approved Enbrel biosimilar
January 18, 2016Manufacturing and Production Benepali, CHMP, EMA, Enbrel, Samsung, Samsung Bioepis, etanercept, positive opinion
Samsung Bioepis – the collaboration between Samsung Biologics and Biogen Idec, has become the first company to have a biosimilar …
Latest content
FibroFind appoints Lee Borthwick as CEO
